Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
prices moving up in the last few days
https://tradingeconomics.com/commodity/lithium
There may be a little more to this latest update than meets the eye. The RNS is worded in such a way that it sounds like someone is strongly hinting about something that is just round the corner but can't let the cat out the bag just yet.
Subtle ramping by TB? Is he really that naive to think words alone will shift the price upwards? .....probably not.
There seems little appetite for this share despite some promising company updates. The bottom will come when the Lithium prices show a sustained increase, this could be sooner than we think. However, very happy to hold so as not to miss any sharp rise on news.
This is why it’s worth a little gamble on this company. Most companies that are able to establish a standard within their field tend to prosper once the technology becomes mainstream. Huge potential here.
https://www.imagingbiometrics.com/wpib/wp-content/uploads/2020/09/IQ-AI-Strategy-Update-IB-Neuro-Standardized-Imaging-Protocol-for-Brain-Tumor-Patients.pdf
Lithium-related stocks have been on a turbocharged run in recent weeks, encouraged by a growing number of cars rolling on to the roads of Europe and China. Shares in Albemarle, the world’s largest producer of the battery raw material, have soared more than two-thirds since their September low. Over the same period, Australia’s Pilbara Minerals has doubled in value.
Howard Klein, founder of RK Equity, which invests in the sector, said equity markets “are pricing in a lithium price rise and they’re going to get a price rise
Any news of actual sales? Do we know who are now IQAI customers paying for their services /products? Has StoneChecker made any sales? If so who to ? What is the value ?
If anyone can answer these questions it will be the biggest clue yet which direction this share is heading
It will be interesting to see an update from Keck medical ref IB Neuro (TM) ref CBV mapping data ? Confirming IB Neuro (TM) standard is proving to be a potential game-changer
https://markets.ft.com/data/announce/detail?dockey=1323-14697470-62TG5FD30BSM6OK9D2HKI4K5GE
Reading between the lines here it looks like many are missing the point of this RNS . StoneChecker V1 has been around a long time and has FDA approval however it seems it was not up the job , thus , limited sales . Feedback from the field meant change was required . It looks like the directors of IQAI have taken on board what is required and invested in changes to ensure that V2 “ does what is says on the tin “ sales can now follow . When you consider the potential that StoneChecker has for affected patients then you realise that this is actually a crucial RNS in terms of IQAI’s potential success going forward.
Great replies gents , we are all gamblers with this share!! I got in at 3.8p a couple of years ago and just sat through the peaks and troughs. I think this one is simple though , I don’t trust Trevor and the article in the Times today sheds light on why.
However TB is very heavily invested in this share and he will want it to succeed, one hopes . Quite simply if the products owned or those marketed by IQAI really work and offer value to the medical institutions that has been claimed, then this share will be worth holding and continue buying into.
If we are all being spun a yarn of epic proportions then as gamblers we should not worry too much and move onto the next fix .